CYTE-I-HD: Phase I dose finding and tolerability study of cysteamine (cystagon in Huntington's disease

Movement Disorders

Volumn 21, Issue 4, 2006, Pages 530-533

  Dubinsky, Richard ^a   Gray, Carolyn ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cysteamine; Hungtington's disease; Transglutaminases inhibitors

Indexed keywords

CYSTAMINE; HYDROGEN SULFIDE; MERCAPTAMINE;

ADULT; ARTICLE; BALANCE IMPAIRMENT; BODY WEIGHT DISORDER; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME; VOMITING; WALKING DIFFICULTY; WEIGHT REDUCTION;

ADULT; CYSTEAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 33646248382     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20756     Document Type: Article

References (22)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Goldberg Y, Nicholson D, Rasper D, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996;13:442-449.
3. Davies S, Turmaine M, Cozens B, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
4. DiFiglia M, Sapp E, Chase K, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993.
5. Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 1993;74:955-956.
6. Cooper A, Jeitner T, Gentile V, Blass J. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q (n)-expansion diseases? Neurochem Int 2002;40:53-67.
7. Karpuj M, Becher M, Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int 2002;40:31-36.
8. Karpuj M, Garren H, Slunt H, et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci U S A 1999;96:7388-7399.
9. Kim S, Grant P, Lee J, Pant H, Steinert P. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 1999;274:15-21.
10. Dedeoglu A, Kubilus J, Jeitner T, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950.
11. Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998;18:117-118.
12. Gahl WA, Thoene JG, Schneider JA. Medical progress: cystinosis. N Engl J Med 2002;347:111-121.
13. Lichtenberger LM, Szabo S, Trier JS. Duodenal ulcerogens, cysteamine and propionitrile, stimulate serum gastrin levels in the rat. Gastroenterology 1977;73:1305-1308.
14. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996; 11: 136-142.
15. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
16. Rhodes V, McDaniel R, editors. Measuring nausea, vomiting and retching. 2nd ed. Boston: Jones and Bartlett; 1997.
17. Detsky AS, Smalley PS, Chang J. Is this patient malnourished? JAMA 1994;271:54-58.
18. Shults C, Steardo L, Barone P, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986;36: 1099-1102.
19. Justino L, Welner SA, Tannenbaum GS, Schipper HM. Long-term effects of cysteamine on cognitive and locomotor behavior in rats: relationship to hippocampal glial pathology and somatostatin levels. Brain Res 1997;761:127-134.
20. Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res 1987;403:234-242.
21. Guillou JL, Micheau J, Jaffard R. Intrahippocampal injections of cysteamine improve the retention of a bar-pressing task in mice. Behav Brain Res 1999;103:113-117.
22. Pinto JT, Van Raamsdonk JM, Leavitt BR, et al. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J Neurochem 2005;94:1087-1101.